ARRT

ARRT – Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

The ARRT trial will assess the safety and efficacy of 2mg aflibercept for the treatment of radiation retinopathy, including maculopathy and optic neuropathy over 52 weeks.

If you would like more information on this study, please click on the link at the top of the page or go to www.clinicaltrials.gov.